Hypotension – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hypotension
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Hypotension – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Hypotension (Cardiovascular), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Hypotension (Cardiovascular) pipeline guide
also reviews of key players involved in therapeutic development for
Hypotension and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 1,
2, 1, 2 and 1 respectively.

Hypotension (Cardiovascular) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Hypotension (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Hypotension
  (Cardiovascular) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Hypotension
  (Cardiovascular) therapeutics and enlists all their major and minor
  projects.
• The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics
  based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Hypotension (Cardiovascular)

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Hypotension (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Hypotension (Cardiovascular) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

• Jan 29, 2019: Theravance doses first patient in Phase II trial of
  ampreloxetine
• Aug 01, 2018: Theravance Biopharma reports positive top-line four-week
  data from phase 2 trial of TD-9855 for the treatment of symptomatic
  neurogenic orthostatic hypotension
• May 29, 2018: TrioxBio Announces Fast Track Designation Granted by
  U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
• Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to
  Submit Marketing Authorization Application for LJPC-501 in the Third
  Quarter of 2018
• Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival
  Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin
  II State
• Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA
  Acceptance of New Drug Application for LJPC-501
• Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of
  Expanded Access Program for LJPC-501
• May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published
  in The New England Journal of Medicine
• Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive
  Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
• Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of
  Allowance for U.S. Patent Covering LJPC-501
• Feb 09, 2015: La Jolla Pharmaceutical Company Announces Special
  Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in
  Catecholamine-Resistant Hypotension
• Jul 08, 2014: La Jolla Pharmaceutical Company Announces Planned
  Initiation of Phase 3 Registration Program for LJPC-501 in Resistant
  Hypotension
• Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II
  Trial Of Droxidopa In Intradialytic Hypotension
• Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II
  Trial Of Droxidopa In Intradialytic Hypotension
• Nov 03, 2008: Chelsea Therapeutics Reports Significant Reduction In
  Severity Of Symptoms During Titration Phase Of Pivotal Droxidopa Study
  In Neurogenic Orthostatic Hypotension

Companies Mentioned

• Cerecor Inc.
• Handa Pharmaceuticals LLC
• La Jolla Pharmaceutical Company
• Theravance Biopharma Inc.
• TrioxBio Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/91um1g

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs